Drug Trial Radar · NCT03657797
Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Last checked: Nov 19, 2026Latest source record: Jun 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
656
Actual
Start
Aug 1, 2018
Primary completion
Aug 23, 2019
Study completion Aug 23, 2019
Sponsor
- Lead sponsor
- Nicox Ophthalmics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 5, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 ophthalmic solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. Three different concentrations of NCX 470 ophthalmic solution (0.021%, 0.042%, and 0.065%) will be compared to latanoprost 0.005% ophthalmic solution.
Conditions
- Glaucoma, Open-Angle
- Hypertension, Ocular
Interventions
NCX 470Drug
NCX 470 Ophthalmic Solution
Latanoprost 0.005%Drug
Latanoprost 0.005% Ophthalmic Solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Study Eye Mean Diurnal IOP at the Week 4Time frame: Baseline, Week 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Texan Eye
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.